Navigation Links
Open access initiative reveals drug hits for deadly neglected tropical diseases
Date:11/13/2012

[Geneva, Switzerland 13 November 2012] - The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box. The resulting DNDi screening data are among the first data generated on the Malaria Box to be released into the public domain, exemplifying the potential of openly sharing drug development data for neglected patients.

The open access Malaria Box is an MMV initiative launched in December 2011 to catalyse drug discovery for malaria and neglected diseases. It contains 400 molecules, selected by experienced medicinal chemists to offer the broadest chemical diversity possible and is available free of charge. In return, MMV requests that any data gleaned from research on the Malaria Box are shared in the public domain within two years. To date, more than 100 Malaria Boxes have been delivered to over 20 countries for research on diseases including malaria, neglected diseases, HIV and cancer.

DNDi, in partnership with the Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, screened all the compounds in the Malaria Box against the parasites responsible for the three NTDs on which DNDi mainly focuses: sleeping sickness (human African trypanosomiasis), leishmaniasis (including visceral leishmaniasis, or kala azar, also known as black fever), and Chagas disease. This initial screen identified two potential drug series for the treatment of sleeping sickness and one for leishmaniasis. The DNDi screens have yielded valuable information that will strengthen DNDi's research pipeline. All the biological data from DNDi's screen, together with the existing preliminary data from MMV, are now publicly available on the open-source ChEMBL database.

"This is a really great example of partnership in action," said Dr David Reddy, MMV's CEO. "MMV and DNDi already work synergistically to tackle tropical diseases. Now, through the Malaria Box we can freely explore molecules that could potentially work against several debilitating tropical diseases, for the benefit of vulnerable populations the world over. It's hugely gratifying to see the idea of the Malaria Box starting to pay off."

Today, DNDi and MMV also announce an agreement to collaborate on drug discovery research by sharing compounds from their respective preclinical pipelines. Compounds provided by DNDi will be screened by MMV for antimalarial activity, and early stage compounds provided by MMV will be assessed by DNDi for their activity against the parasites causing sleeping sickness, leishmaniasis, Chagas disease, and filarial parasitic-worm diseases. This agreement highlights the potential for increased collaboration among Product Development Partnerships (PDPs) like MMV and DNDi to accelerate the development of treatments for some of the world's most neglected diseases and patients.

"Open access initiatives, such as the Malaria Box, are part of an encouraging new paradigm," says Dr Bernard Pcoul, Executive Director of DNDi. "We have to maintain a sharp focus on neglected patient needs and increase our efforts to open up research knowledge, reduce duplication in research efforts, and work together to fill the R&D gaps for diseases that afflict the poorest populations of the world."


'/>"/>

Contact: Oliver Yun
oyun@dndi.org
646-266-5216
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Image share project gives patients and physicians anytime, anywhere access to medical images
2. Equal access to care helps close survival gap for young African-American cancer patients
3. Premier issue of BioResearch Open Access launched by Mary Ann Liebert Inc. publishers
4. World Health Assembly endorses new plan to increase global access to vaccines
5. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
6. Researchers offer new approach to track former prisoners access to community HIV care
7. Revised geographic adjustments could improve accuracy of Medicare payments, will not solve access, quality problems
8. Access to clinical trials drives dramatic increases in survival from childhood cancer
9. Disabled Americans Battle for Access to Hotel Pools
10. Expanding Access to Medicaid Would Save Lives: Study
11. The ACCESS-EU study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed firm ... central Maryland and the DC region, is inaugurating a charity event aimed at fighting ... year, making it the #1 killer in America. However, heart disease is largely preventable, ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... ... ... Hallmark Nameplate, their commitment to quality is what sets them apart. The company is ... another way they are making constant strides to provide all customers with the best ... 13485 Certification is a major accomplishment for Hallmark Nameplate and will allow the company ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist who ... modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. Recently, ... for the Alexandria area. This award confirms the fact that Dr. Qureshi’s patients ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... presenting at the upcoming WCBP Conference, to be held at the Mayflower Hotel, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 The Global Nebulizers Market ... 8.2% over the next decade to reach approximately $1698.68 ... the market is witnessing include rapidly growing demand in ... advancements in nebulizer products and online marketing strategies by ... market is categorized into pneumatic nebulizers, ultrasonic nebulizers and ...
(Date:1/17/2017)... DUBLIN , Jan. 17, 2017  Jazz Pharmaceuticals ... first patient has been enrolled in a Phase 3 ... versus best supportive care (BSC) in the prevention of ... undergoing hematopoietic stem cell transplant (HSCT) who are at ... VOD.  The defibrotide clinical trial will be conducted across ...
(Date:1/17/2017)... -- According to a new market research report "Neural Network Software Market by ... and Region - Global Forecast to 2021" published by MarketsandMarkets, the market to ... at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... ...
Breaking Medicine Technology: